【interviewing in action in a multicultural world 5th edition pdf】Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020
STAMFORD,interviewing in action in a multicultural world 5th edition pdf Conn., May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (
CARA
), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020, at 4:30 p.m. ET to report first quarter 2020 financial results and provide a corporate update.
To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 3875739. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at
www.CaraTherapeutics.com
.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis (PBC).
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
View comments
(责任编辑:Fashion)
- Outlook into the Worldwide Plasma Protein Therapeutics to 2025 - Featuring CSL Behring, Biotest AG & Baxter Among Others
- Were Hedge Funds Right About Chipotle Mexican Grill (CMG)?
- From wagyu beef to melons, Japan's $2.2 trillion virus rescue piques struggling firms
- Sientra to Present at the William Blair 40th Annual Growth Stock Conference
- FTC Sending More Than $470K to People Duped by My7Network, ‘Bitcoin Funding Team’ Scams
- Endurance International (EIGI) Q3 Earnings and Revenues Surpass Estimates
- Sonoco Implementing Price Increases for All Rigid Paper Containers and Closures
- Maybe the Coronavirus Didn’t End the Bull Market
- Is Now The Time To Look At Buying National Beverage Corp. (NASDAQ:FIZZ)?
- XFC to Live Stream Inaugural Try-Outs in Michigan on Sept 12 Live on Location at Team SFS-Scorpion Fighting System
- Is There Now An Opportunity In Sotherly Hotels Inc. (NASDAQ:SOHO)?
- Oil Price Fundamental Daily Forecast – OPEC+ to Discuss Production Cut Extension to September 1
- Can You Imagine How Eagle Nice (International) Holdings's (HKG:2368) Shareholders Feel About The 96% Share Price Increase?
- CORRECTED-Fed's Evans says U.S. should support workers who lose pay if coronavirus worsens
- Apple Tells Staff U.S. Stores to Remain Closed Until Early May
- Apple's New Deal With Amazon Prime Video Is a Game Changer
- Exclusive: StanChart says CEO Winters will stay to execute current strategy
- AppFolio, Inc. Announces First Quarter 2020 Financial Results
- Robin.io Expands Leadership Team and Advisory Board for 5G Market
- Great Ajax (AJX) Misses Q4 Earnings and Revenue Estimates